Loading...
•
Mar 31
Guardant Health Q1 2025 Earnings Report
reported financial results for the first quarter ended March 31, 2025
Key Takeaways
Guardant Health reported strong revenue growth of 21% in Q1 2025, driven by solid performance in oncology, screening, and biopharma & data segments. The company also increased its full-year 2025 revenue guidance.
Total revenue increased 21% to $203.5 million compared to the prior year period.
Oncology revenue grew 20% to $150.6 million, with a 25% increase in oncology test volume.
Screening revenue was $5.7 million, generated from approximately 9,000 Shield screening tests.
Biopharma & Data revenue increased 21% to $45.4 million.
Guardant Health
Guardant Health
Guardant Health Revenue by Segment
Revenue by Segment
Oncology Revenue
CapyFin.comBiopharma and Data Revenue
CapyFin.comScreening Revenue
CapyFin.comLicensing and Other Revenue
CapyFin.com Forward Guidance
Guardant Health raised its full-year 2025 revenue guidance and provided updated expectations for oncology, screening, and biopharma & data revenue growth.
Positive Outlook
- Full year 2025 revenue guidance raised to $880 to $890 million, representing 19% to 20% growth.
- Oncology revenue expected to grow approximately 18% year over year in 2025.
- Oncology volume expected to accelerate to greater than 25% growth in 2025.
- Screening revenue expected in the range of $40 to $45 million, driven by Shield volume of 52,000 to 58,000 tests.
- Free cash flow burn expected to improve to $225 to $235 million for the full year 2025.
Challenges Ahead
- Total non-GAAP operating expenses expected to increase to $830 to $840 million.
- The increase in non-GAAP operating expenses is due to reinvestment of incremental Screening gross profit to accelerate commercial infrastructure build out.
- Free cash flow burn includes approximately $200 million of screening net cash burn.
Revenue & Expenses
Visualization of income flow from segment revenue to net income